OpenLB
Open Library of Bioscience
Advanced Search
The Nurse practitioner
11 01, 2022;47 (11): 40-47.

Pneumococcal vaccination for adults: History and updates.

Jana L Esden
Author Information
  1. Jana L Esden: Jana L. Esden is an associate professor at Frontier Nursing University in Versailles, Ky and a member of The Nurse Practitioner Editorial Advisory Board.
PMID: 36287736 DOI: 10.1097/01.NPR.0000897220.84850.82

Abstract

ABSTRACT: Although pneumococcal vaccination programs have significantly reduced the incidence of pneumococcal infections in the US, pneumococcal pneumonia continues to be a burdensome cause of morbidity and mortality. Pneumococcal vaccination recommendation updates were recently published and introduce two new pneumococcal conjugate vaccines for use in adults ages 19 and older.

References

  1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019 - Streptococcus pneumoniae report. www.cdc.gov/drugresistance/pdf/threats-report/strep-pneumoniae-508.pdf . Accessed July 24, 2022.
  2. National Heart Lung, and Blood Institute. Pneumonia. www.nhlbi.nih.gov/health-topics/pneumonia . Accessed July 24, 2022.
  3. Centers for Disease Control and Prevention. Pneumococcal disease. www.cdc.gov/pneumococcal/clinicians/clinical-features.html . Accessed July 24, 2022.
  4. Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National Health Interview Survey, 2019-2020. www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2019-2020.html . Accessed July 15, 2022.
  5. McLaughlin JM, Swerdlow DL, Khan F, et al. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Hum Vaccin Immunother . 2019;15(4):841–849.
  6. Gatwood J, Chiu C-Y, Shuvo S, et al. Role of social determinants of health in pneumococcal vaccination among high-risk adults. Vaccine . 2021;39(14):1951–1962.
  7. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 1997;46(RR-08):1–24.
  8. Gierke M, Wodi AP, Kobayashi M. Pneumococcal disease. www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html#epidemiology . Accessed July 24, 2022.
  9. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP) update: pneumococcal polysaccharide vaccine usage — United States. MMWR Morb Mortal Wkly Rep . 1984;33(20):273–276,281.
  10. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 2000;49(RR-09):1–38.
  11. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Am J Prev Med . 2015;49(6 suppl 4):S383–S390.
  12. U.S. Food and Drug Administration. Pneumococcal 7-valent conjugate vaccine (Diphtheria CRM197 Protein). www.fda.gov/media/76076/download . Accessed July 24, 2022.
  13. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep . 2010;59(9):258–261.
  14. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 2012;61(40):816–819.
  15. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep . 2012;61(21):394–395.
  16. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 2014;63(37):822–825.
  17. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 2015;64(34):944–7.
  18. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years. MMWR Morb Mortal Wkly Rep . 2019;68(46):1069–1075.
  19. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep . 2022;71(4):109–117.
  20. Merck. U.S. FDA Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children. www.merck.com/news/u-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children/ . June 22, 2022.
  21. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep . 2022;71(37):1174–1181. Published 2022 Sep 16. doi:10.15585/mmwr.mm7137a3
  22. Vadlamudi NK, Chen A, Marra F. Impact of the 13-valent pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis. Clin Infect Dis . 2019;69(1):34–49.
  23. Blasi F, Mantero M, Santus PA, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect . 2012;18(suppl 5):7–14.
  24. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol . 2009;9(3):213–220.
  25. Clutterbuck EA, Lazarus R, Yu L-M, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis . 2012;205(9):1408–1416.
  26. Demczuk WHB, Martin I, Desai S, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016. Vaccine . 2018;36(31):4701–4707.
  27. Naucler P, Galanis I, Morfeldt E, Darenberg J, Ortqvist Å, Henriques-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis . 2017;65(11):1780–1790.
  28. Essink B, Sabharwal C, Cannon K, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis . 2022;75(3):390–398.
  29. Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 18 through 49 years of age. Vaccine . 2021;39(38):5428–5435.
  30. Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine . 2021;39(51):7494–7502.
  31. Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18–49 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY). Open Forum Infect Dis . 2021;9(3):ofab605.
  32. Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine . 2022;40(1):162–172.
  33. Simon JK, Staerke NB, Hemming-Harlo M, et al. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-TRUE). Vaccine . 2022;40(9):1342–1351.
  34. Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf . Accessed July 15, 2022.
  35. U.S. Food and Drug Administration. Package insert - PREVNAR 20. www.fda.gov/media/149987/download . Accessed July 24, 2022.
  36. U.S. Food and Drug Administration. Package insert – VAXNEUVANCE. www.fda.gov/media/150819/download . Accessed July 24, 2022.
  37. Raman R, Brennan J, Ndi D, et al. Marked reduction of socioeconomic and racial disparities in invasive pneumococcal disease associated with conjugate pneumococcal vaccines. J Infect Dis . 2021;223(7):1250–1259.
  38. Pfizer. Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants. www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20 . August 12, 2022.

MeSH Term

Adult
Humans
Young Adult
Vaccines, Conjugate
Pneumococcal Vaccines
Pneumococcal Infections
Pneumonia, Pneumococcal
Vaccination

Chemicals

Vaccines, Conjugate
Pneumococcal Vaccines
Journal Article

Word Cloud

Created with Highcharts 10.0.0pneumococcalvaccinationPneumococcalupdatesABSTRACT:AlthoughprogramssignificantlyreducedincidenceinfectionsUSpneumoniacontinuesburdensomecausemorbiditymortalityrecommendationrecentlypublishedintroducetwonewconjugatevaccinesuseadultsages19olderadults:History

Similar Articles

Cited By

No available data.